ArticleAdvances in radiation oncology2025
Treatment Outcomes and Prognostic Factors for Patients With Medulloblastoma Having Defined Molecular Subtypes.
Article in Advances in radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Tumor Microenvironmental Regulation of CAR T-Cell Therapy in High Risk Medulloblastoma.Research square · 2026Article
- Antigen Specificity and Cell Engineering Determine CAR T Cell Efficacy in Group 3 Medulloblastoma.Research square · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aims to evaluate treatment outcomes and prognostic factors in pediatric patients with medulloblastoma (MB) with defined molecular subtypes to inform subsequent individualized treatment. Methods and Materials: A retrospective analysis was conducted on 145 patients with MB with defined molecular subtypes who underwent radiation therapy (RT) at our institution from January 2017 to 2021. Patients were subjected to traditional clinical risk stratification, molecular risk stratification, and National Comprehensive Cancer Network (NCCN) risk stratification, respectively. The treatment outcomes and associated prognostic factors were analyzed. Results: With a median follow‑up of 49 months, the 5-year event-free survival (EFS) and overall survival rates were 68.6% ± 4.0% and 74.7% ± 4.4%, respectively. Multivariate analysis revealed that failure to achieve a complete response after RT (5-year EFS 39.3% ± 9.2% vs 75.7% ± 4.2%; Conclusions: MB is a heterogeneous disease that requires the integration of clinical and molecular features for defined risk stratification to facilitate individualized treatment. In this study, we found that residual disease after RT, fewer than 6 cycles of chemotherapy, and high-risk NCCN risk stratification were independent adverse prognostic factors for patients with MB.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.